|
KR20150128952A
|
|
Topical compositions of flunisolide and methods of treatment
|
|
EP2968572A1
|
|
Topical compositions of flunisolide and methods of treatment
|
|
KR20160021074A
|
|
Controlled release pharmaceutical dosage forms
|
|
US2014206735A1
|
|
High dosage topical metronidazole aqueous-based gel formulations and their use to treat rosacea
|
|
US2014323516A1
|
|
Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
|
|
US2014274970A1
|
|
Controlled release pharmaceutical dosage forms
|
|
AU2013204997A1
|
|
Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
|
|
WO2013040447A2
|
|
Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
|
|
WO2013019974A1
|
|
Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
|
|
CA2840571A1
|
|
High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
|
|
CA2771520A1
|
|
Methods of evaluating normalcy of lips and safety of lip treatments
|
|
CA2802518A1
|
|
Mid-face aesthetic scale and related methods
|
|
AU2011270724A1
|
|
Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
|
|
US2011112153A1
|
|
Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
|
|
NZ601021A
|
|
Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
|
|
WO2010144659A1
|
|
Methods for measuring change in lip size after augmentation
|
|
AU2010274097A1
|
|
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
|
US2010215744A1
|
|
Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
|
|
WO2010115164A1
|
|
Topical compositions
|
|
WO2010101934A1
|
|
Methods and compositions for treating acne
|
